Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (August 2026)
29 slides from Prescient Therapeutics's investor presentation, Aug 26, 2026
Slide 1: SPP Presentation
SPP Presentation Join the CEO of PTX James McDonnell for a live and interactive shareholder briefing on Friday, 28th August 11am (AEST) where he will discuss the Share Purchase Plan, use of funds and how to participate. Register here: https://prescienttherapeutics.investorportal.com.au/shareholder-b
Slide 2: About Prescient Therapeutics Limited (Prescient)
About Prescient Therapeutics Limited (Prescient) Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms. Targeted Therapy PTX-100 is a first-in-class compound with the ability to
Slide 3: Shareholder Briefing
For personal use only Shareholder Briefing August 2026 ASX: PTX ptxtherapeutics.com
Slide 4: Disclaimer and Safe Harbour
Disclaimer and Safe Harbour For personal use only Certain statements made in this document are forward-looking statements within the Certain statements contained in this document, including, without limitation, meaning of the safe harbor provisions of the United States Private Securities Litigation
Slide 5: Company snapshot: Key Metrics
Company Key Metrics snapshot ASX Ticker PTX For personal use only Total Issued Capital 1,051 M shares Share Price1 A$0.072 Market Capitalisation1 A$76 M Cash Position2 A$9.03M Top 20 Own 21% 1. As at 24 August 2026 2. As at 30 June 2026 listed in Annual Report 21 August 2026 3
Slide 6: Highlights
Highlights For personal use only PTX-100 Pioneering a drug First-in-class drug candidate Lead drug candidate platform with the (PTX-100) licensed from Yale potential to address ~1 in Most clinically advanced University 5 cancers1 against its target 2 Rare blood cancer initial Near-term milestone exp
Slide 7: Background
For personal use only Background
Slide 8: What causes cancerous mutations?
What causes cancerous mutations? For personal use only Normal cell growth Normal cell Cell division Healthy tissue Abnormal cell growth Normal cell Genetic changes Cancerous cell division Malignant tumour Mediated by the RAS family Source: https://www.cancerfoundation.org.au/what-is-cancer-.html mod
Slide 9: How PTX-100 works
How PTX-100 works RAS proteins can drive overgrowth of cells through PTX-100 blocks GGTase-1, For personal use only many signaling pathways, regulated by GGTase-1 broadly inhibiting RAS proteins signaling Cell Cell me me mb mb ra ra ne ne RAS GGTase-1 RAS Family Family GGTase-1 ON ON PTX-100 OFF OFF
Slide 10: A clever design for specific inhibition
A clever design for specific inhibition For personal use only AI- and physics-based modelling CEllular Thermal Shift Assay (CETSA®) Percentage of anchored-prenylated Rap1 PTX-100 does not require the presence of the PTX-100 exhibits strong binding to its cellular PTX-100 inhibition of GGTase-I induc
Slide 11: First-in class advantages
First-in class advantages For personal use only First and only GGTase-1 inhibitor to reach clinical development1 This position potentially allows Prescient Therapeutics to: Eligibility for favorable regulatory designations that may support expedited development timelines2 Move through development wi
Slide 12: PTX-100 for CTCL
For personal use only PTX-100 for CTCL
Slide 13: Strategy and data
Strategy and data For personal use only First indication Selection Outcomes chosen for: made: CTCL so far PTX-100: • Strong RAS involvement • RAS family involvement • Phase 1b results: 43% objective response rate2 and • High unmet need • Orphan disease no drug-related serious • Strong chance of • Ad
Slide 14: CTCL is a challenging disease
CTCL is a challenging disease For personal use only • Rare type of white blood cell (T cell) cancer • Cancerous T cells attack skin, eventually impacting nodes, viscera and blood • Significantly impacts quality of life ➢ Pruritus (itching) ➢ Secondary infections ➢ Appearance impacted by skin involve
Slide 15: Not all CTCL patients are the same
Not all CTCL patients are the same Poor Outcomes in Advanced Stages For personal use only 5 Year Overall Survival (%) Mycosis Fungoides (MF) IA 94% MF Early-Stage • Most common CTCL subtype (~50- • Existing treatment options are 70% of cases); indolent, skin-limited IB 84% poor with current drugs pr
Slide 16: A differentiated mode of action
A differentiated mode of action For personal use only Lymphir® Adcetris® Poteligeo® Campath® *IPH4120 *BI-1808 Receptor DT MMAE TYR Kinase IL-2 Cell Induced Death Cytotoxicity CD25 CD30 CCR-4 CD52 KIR3DL2 TNFR2 RAS Family Protein GRB2 SOS GTP PTX-100 approach PTX-100 Cell death; reduced migration, s
Slide 17: Phase 1b sub-analysis of CTCL patient cohort
Phase 1b sub-analysis of CTCL patient cohort CTCL response rates, safety and duration including consideration of other therapies are key drivers to initiation of Phase 2 For personal use only PTX-100 Benchmark1 Lymphir2,3 Poteligeo4 Lacutamab5,6 (CTCL only) 7 Objective Response 42.9% (SS) 30% 36% 28
Slide 18: PTX-100: Favourable safety profile compared to peers
PTX-100: Favourable safety profile compared to peers Recommended CTCL drugs have challenging safety profiles, with adverse events occurring in up to 70% of patients For personal use only Adverse events associated with current marketed drugs and PTX-100 PTX-100 has a favourable safety profile • Data
Slide 19: Progressing PTX-100 Through Phase
Progressing PTX-100 Through Phase 2 Phase 2 Endpoints For personal use only Primary endpoint: r/r CTCL (MF & SS) 500mg/m2 x • Objective Response Rate (ORR) 2 lines of prior 20 pts Secondary endpoints: systemic Dose Phase 2a • Skin response using mSWAT treatment Optimisation Dose Optimisation • Progr
Slide 20: PTX-100 (CTCL): Clinical Trial Plan
PTX-100 (CTCL): Clinical Trial Plan Completed Ongoing Expected Clinical Plan Potential Clinical Plan For personal use only Ph 1b Ph 2a Ph 2b Ph 3 MA On Market Pivotal MA On Market Safety Dose Efficacy Confirmatory Confirmatory Study finding and study efficacy and efficacy and efficacy safety studies
Slide 21: Total addressable market
Total addressable market High unmet need = large market opportunity For personal use only US market for CTCL • 3,0001 new CTCL cases per year in the US • Estimated US CTCL market size of approximately ~US$1.2bn / year by 20342 1. JAMA Oncology.2022 Sep1;8(11):1690–1692.doi:10.1001/jamaoncol.2022.323
Slide 22: New entrants for CTCL can grow the market
New entrants for CTCL can grow the market For personal use only CTCL US Market 2020 to 20251(US$M) $800 $700 $600 Early results position PTX-100 well $500 against current therapies $400 $300 • Enable market share growth $200 • Unique MOA supports $100 combination opportunities $0 2020 2021 2022 2023
Slide 23: Expansion strategy
Expansion strategy For personal use only Stage 1: CTCL-centric Stage 2: Expansion Demonstrate efficacy & safety • Bring new indications onto platform FDA support (ODD, FTD) • Progressively address further cancers • Complete registrational study • Strategic commercial pathways • CTCL commercial pathw
Slide 24: Key Events and Upcoming Milestones for PTX-100
Key Events and Upcoming Milestones for PTX-100 ✓ Q1 2023 Orphan Drug Designation for all TCL – US FDA Q4 2026 DOC review, 20 evaluable patients For personal use only ✓ Q4 2024 IND cleared for Phase 2a trial – US FDA 1H 2027 France sites open ✓ Q1 2025 First Phase 2a site initiated 1H 2027 Phase 2a e
Slide 25: Board and management
Board and management Experienced team of drug developers and deal makers with track record in blood cancers For personal use only Management Team Experienced gained in global companies James McDonnell Dr Rebecca Tunstall Dr Rosalind Wilson Upaly Bahadure Dr Luis Malaver-Ortega CEO COO Chief Medical
Slide 26: Our unique value proposition
Our unique value proposition First-in-class approach to a proven pathway For personal use only Pioneering First disease target (CTCL) technology delivering strong data • One of the most advanced cancer therapies on the ASX • PTX-100 is the most advanced • Efficacy signals seen in Phase 1b results se
Slide 27: Share Purchase Plan
For personal use only Share Purchase Plan ptxtherapeutics.com 25
Slide 28: Summary of the SPP
Summary of the SPP For personal use only SPP Offer Raise Amount Targeting $7 million The proceeds from the SPP will support the ongoing development of the Company's first-in-class cancer treatment, PTX-100, allowing the Company to advance its targeted therapy beyond the Dose Optimisation Committee r
Slide 29: Thank you
For personal use only Thank you August 2026 ASX: PTX ptxtherapeutics.com 27
Prescient Therapeutics — Investor Presentation (August 2026) on 6ix